<DOC>
	<DOC>NCT02888496</DOC>
	<brief_summary>Pathophysiology of polymyalgia rheumatica (PMR) is ill defined. This study aims at characterizing immunological abnormalities in PMR patients, and to assess the effects of tocilizumab therapy on this abnormalities.</brief_summary>
	<brief_title>Lymphocyte and Cytokine Disturbances in Polymyalgia Rheumatica</brief_title>
	<detailed_description>Comparison of PMR patients and matched control subjects.</detailed_description>
	<mesh_term>Polymyalgia Rheumatica</mesh_term>
	<mesh_term>Giant Cell Arteritis</mesh_term>
	<criteria>PMR patient included in the TENOR study with samples available Patient not included in the TENOR study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>